

U.S.S.N.: 08/480,850

Filed: June 7, 1995

SUBMISSION UNDER 37 C.F.R. §1.129(a)

THIRD AMENDMENT AND RESPONSE TO OFFICE ACTION

account the claim of priority, the present application was pending for at least two years as of June 8, 1995. The Examiner is authorized to charge Deposit Account 10-1215 the large entity fee for filing this submission under 37 C.F.R. §1.129(a).

In the Claims

Please amend the claims by inserting the underlined words and deleting the words in brackets as follows:

7. (thrice amended) [Pure] Recombinant herpes simplex virus gG-1 antigen produced by employing a recombinant baculovirus having the 5' nontranslated leader sequence of the polyhedrin gene joined to the coding region of a foreign gene precisely at the translation initiation codon of the polyhedrin gene, without either missing any nucleotide present in said initiation codon or introducing any extraneous nucleotide at the initiation codon site, wherein said foreign gene is herpes simplex virus type 1 glycoprotein gene.

8. (thrice amended) [Pure] Recombinant herpes simplex virus gG-2 antigen produced by employing a recombinant baculovirus having the 5' nontranslated leader sequence of the polyhedrin gene joined to the coding region of a foreign gene precisely at the translation initiation codon of the polyhedrin gene, without either missing any nucleotide present in said initiation codon or introducing any extraneous nucleotide at the initiation codon site, wherein said foreign gene is herpes simplex virus type 2 glycoprotein gene.

16. (amended) A composition [.] comprising pure recombinant baculovirus expressed [hespes] herpes simplex virus gG-1 or herpes simplex virus gG-2 antigen in a pharmaceutically acceptable carrier.

REMARKS

The present application is directed to recombinant antigens produced by baculovirus expression vectors, particularly the herpes simplex virus types 1 and 2 glycoprotein antigens designated glycoprotein G-1 (gG-1) and glycoprotein G-2 (gG-2). The baculovirus system